Drug Type Fusion protein |
Synonyms Hexameric FasL(University of Lausanne) |
Target |
Mechanism FasL agonists(Soluble Fas ligand agonists), Apoptosis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 2 | DK | 13 Jun 2017 | |
Refractory Multiple Myeloma | Phase 2 | DK | 13 Jun 2017 | |
Relapse multiple myeloma | Phase 2 | DK | 13 Jun 2017 | |
Non-Small Cell Lung Cancer | Phase 1 | CH | 01 Feb 2007 | |
Ovarian Cancer | Phase 1 | CH | 01 Feb 2007 | |
Neoplasms | Preclinical | CH | 27 Mar 2023 | |
Neoplasms | Preclinical | CH | 27 Mar 2023 | |
Hematologic Neoplasms | Preclinical | CH | - |